Products For Flu, Lung Cancer, HIV And TTP Enter Final Stages Of Assessment In EU
Products in the final stages of pre-marketing evaluation at the European Medicines Agency include drugs for influenza, NSCLC, aTTP and HIV infection.
You may also be interested in...
The European Medicines Agency's drug evaluation committee, the CHMP, will this week decide whether up to a dozen products that have been through the evaluation process should be recommended for approval in throughout the EU.
Nine marketing authorization applications, 15 variation of therapeutic indication requests, two requests for accelerated assessment and a re-examination procedure. These are some of items on the agenda at the latest meeting of the EMA’s key advisory panel, the CHMP, which is under way in London.
The first meeting this year of the European Medicines Agency’s key scientific committee, the CHMP, is under way in London, with a number of new drugs up for a marketing authorization recommendation.